Have to say that Medidata EDC Rave is not a system any investigator will ever rave about (now if they called it Rage…) It just reached a new level today for me as after 10+ yrs of use was just required to do a highly instructive training module on “how to activate my account”.

A win for science and humanity! !science.org/content/articl…

New lung cancer cases vary by state, and early diagnosis is key. The 2024 #StateOfLungCancer report explains how each state measures up and why it matters. Lung.org/solc

Can ADCs be a game changer?” Insightful talk by Dr. Adjei highlighting presented/published trials of ADCs. With continued biomarker refinement and novel payload-target combinations, can we make further strides? DAVA Oncology #HawaiiLung25

The saga continues. Intriguing and provocative. Some key questions remain to be resolved...

Great improvements over time. Still so much more to do for our patients and families.

It is sounding quite romantic indeed. 🥂🙌🎉

Lung cancer took the life of another one of my patients today, only 48. A Veteran. Spirit unbreakable, great sense of humor. Despite advances, another reminder of the need for more progress as research funding gets thinner. Where do we go? How do we get there?

Wow. That is it. Just Wow. 😅😂🎉🎉🎉

🙏🙏🙏🏆

Majestic creatures. Both of them.

The U.S. FDA granted accelerated approval to the EGFR inhibitor sunvozertinib for certain adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations: brnw.ch/21wTRc7

The more the merrier. Keep them coming for our patients...

Looks like diarrhea can still be a barrier to patients to benefit from it. Nice option nonetheless in this difficult group of disease.

🆕 Nature study on #lungcancer in never-smokers challenges long-held assumptions. ✅ Air pollution linked to key mutations ✅ EGFR most common in East Asia ❌ Secondhand smoke not a major factor - minimal genomic impact 68% of our EGFR+ UK members (2024 data) are never-smokers

🚀 Advancing CAR T Cell Therapy for Solid Tumors Current CAR T therapies face challenges in solid tumors due to immunosuppression and antigen diversity. To tackle this, researchers developed 'armoured' CAR T cells that secrete proinflammatory cytokines — but safety concerns have

We are not only in critical shortabe of drugs, but also critically short of hematologists/oncologists. ASCO predicted U.S. will be in shortage of 2,200 heme/oncologists by 2025 (i.e. Now). We need quick solutions. 🙏🙏🙏#ASCO ASCO

As a thoracic oncologist, I have seen hundreds of patients with lung cancer (NSCLC and SCLC) being treated under standard of care or a clinical trial (my passion). Lung cancer therapies significantly started to expand in the early 2010s. In recent weeks, we have had several

Happy July 4th!!! 💝

Happy visiting 😊 my daughter on this special July 4th weekend, in Boston where I started 😀 😎 my U.S. 🇺🇸 journey 1996 from 🇨🇦 🍁 Catching up with sweet memories ❤️ of early training here.